Archive forH1N1 SWINE FLU INFO

New Patterns in H1N1 Deaths

SAO PAULO, Dec. 23 (UPI) — In a Brazilian study, 76 percent of the patients who died of H1N1 had underlying medical conditions such as heart disease or cancer, researchers say.

However, lead author Dr. Thais Mauad of Sao Paulo University in Brazil said there was no clear complicating medical condition in the remaining one-quarter.

Mauad and colleagues examined 21 patients who had died in Sao Paulo with confirmed H1N1 infection in July and August. Most were 30 to 59.

While previous data has shown most patients with a non-fatal infection have fever, cough and achiness, but “most patients with a fatal form of the disease presented with difficulty breathing, fever and achiness being less frequently present.”

All patients died of severe acute lung injury, but there were three distinct patterns of the damage to their lungs, indicating that the infection killed in distinct ways.

“All patients have a picture of acute lung injury,” Mauad says in a statement. “In some patients this is the predominant pattern, in others, acute lung injury is associated with necrotizing bronchiolitis, and in others there is a hemorrhagic pattern.”

Patients with necrotizing bronchiolitis are more likely to have a bacterial co-infection, patients with heart disease and cancer are more likely to have a hemorrhagic condition in their lungs, Mauad says.

Comments

H1N1 and Immunocompromised Patient Care from the CDC

Updated Interim Recommendations: Special Considerations for Clinicians Regarding 2009 H1N1 Influenza in Severely Immunosuppressed Patients

December 16, 2009, 11:30 AM ET

Epidemiology

Immunosuppression can result from a variety of clinical conditions, and the severity of immunosuppression may vary with the severity of the condition. Immunosuppression may also result from immunosuppressive treatments, the extent of which may depend on factors such as dosage or synergistic medication combinations. Some common conditions and treatments associated with immunodeficiency are shown in the tables below. These interim recommendations refer to patients who are severely immunosuppressed as a result of receiving treatment for malignancies; or as a result of receiving treatment related to solid organ or hematopoietic stem cell transplants; or as a result of autoimmune conditions and treatment. Such patients may be at high risk of influenza-related complications such as more severe illness and hospitalization. These recommendations may be updated as further information becomes available. In addition to this guidance, there are documents available for caregivers of adult and adolescent HIV-infected patients as well as for patients with rheumatological diseases.

Patients with severe immunosuppression from the following conditions or treatments may be at high risk for influenza-related complications.

Some Conditions and Treatment that Suppress the Immune System*
  • Hematopoietic stem cell transplant recipient receiving anti-rejection medication
  • Solid organ transplant recipient receiving anti-rejection medication
  • Congenital immunodeficiency disorder
  • Chemotherapy for cancer
  • Autoimmune conditions and treatments
  • Chronic corticosteroid use

* HIV and Rheumatologic conditions are included in other guidance

Patients with conditions that confer some degree of immunosuppression, e.g., asplenia, may not necessarily have increased risk for influenza-associated complications, but may be at high risk for secondary invasive infection with encapsulated bacteria (e.g., pneumococcal disease).

Patients who use short courses of treatments that weaken the immune system for mild, common ailments (e.g., corticosteroid use for poison ivy), are likely NOT at increased risk of complications from influenza unless they also have other high-risk conditions for influenza complications such as asthma, chronic obstructive pulmonary disease, diabetes, heart disease, pregnancy, cancer, etc.

Clinical Issues

While some severely immunosuppressed patients may develop typical signs and symptoms of influenza, fever may not always be present1. Therefore, clinicians should suspect influenza in any severely immunosuppressed patient with acute respiratory symptoms, with or without fever, and initiate empiric antiviral treatment as soon as possible and send respiratory specimens for real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) (see Influenza diagnostic testing and Antiviral treatment sections below). Appropriate infection control including isolation should be implemented for any suspected patient as soon as possible even before testing results are available.

Although the type and severity of immune dysfunction that correlates with increased risk of influenza-associated complications is not well defined, transplant patients with significant lymphodepletion (i.e., lymphopenia due to immunosuppression for recent hematopoietic stem cell transplant) or lymphocyte dysfunction have had serious complications of influenza virus infection, prolonged viral shedding, and have acquired resistance to antiviral medications2. Sporadic cases of oseltamivir-resistant 2009 H1N1 influenza virus infection have been reported; some of these cases were in severely immunosuppressed patients in whom resistance emerged during treatment for symptomatic illness and who experienced prolonged viral shedding3. Therefore, some experts have recommended that immunosuppressed patients with 2009 H1N1 influenza virus infection should strictly adhere to recommended personal protective equipment and infection control measures until symptoms have resolved and there are serial respiratory specimens that test negative for 2009 H1N1 viral RNA by rRT-PCR 4, 5.

Influenza vaccination and prevention

Although influenza vaccination is the best way to prevent influenza, influenza vaccination may be poorly immunogenic in severely immunosuppressed patients6. Therefore, antiviral chemoprophylaxis of influenza can be considered for severely immunosuppressed patients7. Immunosuppressed persons aged 6 months and older are recommended to receive both inactivated seasonal influenza vaccine and inactivated 2009 H1N1 monovalent influenza vaccine. In addition, persons aged 6 months and older who are household contacts of severely immunosuppressed persons are recommended for annual inactivated seasonal influenza vaccination. Further details regarding reasons for vaccinating these groups can be found in the 2009 H1N1 Vaccination Recommendations.

Influenza diagnostic testing

Any severely immunosuppressed patient who is ill with suspected influenza should be started on empiric antiviral treatment as soon as possible without waiting for influenza testing to be conducted or influenza testing results. Confirmatory influenza diagnostic testing for 2009 H1N1 influenza with rRT-PCR should be considered for severely immunosuppressed patients with suspected influenza because results will inform decisions regarding clinical care and infection control. Additional influenza testing of respiratory specimens of severely immunosuppressed patients by rRT-PCR is recommended by some experts for determination of prolonged viral shedding. Guidelines for influenza testing in solid organ or hematopoietic stem cell transplant donors with suspected influenza are available8, 9. Recommendations on the use of influenza diagnostic tests for the 2009-2010 influenza season are available.

Antiviral treatment

Antiviral therapy with a neuraminidase inhibitor (oseltamivir, zanamivir) should be initiated empiricallyas early as possible for severely immunosuppressed patients with suspected influenza. Although efficacy of early antiviral treatment (<48 hours from illness onset) of previously healthy persons with uncomplicated influenza has been demonstrated in randomized clinical trials, observational studies indicate that initiation of oseltamivir treatment after 48 hours of onset in hospitalized patients with seasonal influenza or 2009 H1N1 is associated with survival benefit compared to no treatment10, 11, 12, 13. Although there are no prospective data available for neuraminidase inhibitor treatment of immunosuppressed patients with influenza, initiation of therapy beyond 48 hours after symptom onset should be considered.

Clinicians should be aware that severely immunosuppressed persons with influenza may experience prolonged influenza viral replication; those with significant lymphopenia will typically shed for longer than 5 days even with antiviral treatment2. Therefore, some experts have recommended consideration of longer duration of neuraminidase inhibitor treatment (e.g. 10 days versus standard 5 days). Infection control precautions should be maintained for as long as such patients have evidence of prolonged influenza viral shedding as detected by rRT-PCR and/or remain symptomatic – whichever is longer. Sporadic cases of oseltamivir resistant 2009 H1N1 virus have been reported in severely immunosuppressed patients who were treated with oseltamivir. This oseltamivir resistance is associated with an H275Y mutation in viral neuraminidase. Patients with suspected or confirmed oseltamivir-resistant 2009 H1N1 influenza virus who require antiviral treatment should receive zanamivir. If orally inhaled zanamivir is contraindicated or not tolerated, then IV zanamivirExternal Web Site Icon is available for compassionate use from its manufacturer via an emergency Investigational New Drug (IND) application to the FDA. Patients with highly suspected or documented oseltamivir resistance should not be treated with peramivir because clinical isolates expressing the oseltamivir resistance-associated substitution H275Y in neuraminidase have demonstrated reduced in-vitro susceptibility to peramivir, although the clinical significance of this is currently unknown. Development of resistance to other antiviral medications during treatment is also possible. Such antiviral resistance would be associated with different mutations and can only be detected by robust screening assays that are not specific for the H275Y mutation. Clinicians managing 2009 H1N1 hospitalized patients who have not improved clinically and who have persistent laboratory-confirmed viral shedding may wish to consult infectious disease specialists, their state health department or CDC for questions about antiviral resistance, additional testing and antiviral treatment.

Optimal therapy for severely immunosuppressed patients with oseltamivir-resistant 2009 H1N1 influenza virus has not been defined. Some severely immunosuppressed patients with 2009 H1N1 have been treated with a combination of IV zanamivir and aerosolized ribavirin3, 14 therapy, or IV zanamivir monotherapy15. Clinicians should note that orally inhaled zanamivir may not be tolerated by critically ill patients with lower respiratory tract disease. Clinicians should be aware that intravenous antiviral medications are available, IV peramivir16 through an Emergency Use Authorization; and IV zanamivir15 through an Emergency Investigational New Drug Application) for treatment of critically ill 2009 H1N1 patients or for hospitalized patients who cannot tolerate orally inhaled zanamivir or oral oseltamivir when treatment is indicated. Critically ill immunosuppressed patients are particularly susceptible to secondary bacterial and fungal infections that can cause pneumonia and disseminated infection, including sepsis, and should be empirically treated with antibiotics based on clinical judgment.

1 Peck AJ, Englund JA, Kuypers J et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007 Sep 1;110(5):1681-8.
2 Khanna N, Steffen I, Studt JD et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009 Apr;11(2):100-5.
3 CDC. Oseltamivir-Resistant Novel Influenza A (H1N1) Virus Infection in Two Immunosuppressed Patients — Seattle, Washington, 2009. MMWR, 2009. 58(32);893-896.
4 Gooskens J et al. Prolonged Influenza Virus Infection during Lymphocytopenia and Frequent Detection of Drug-Resistant Viruses. The Journal of Infectious Diseases 2009; 199:1435– 41
5 Lee N, Chan PK, et al. Viral Loads and Duration of Viral Shedding in Adult Patients Hospitalized with Influenza. J Infect Dis. 2009; 200:492-500.
6 Hodges GR, Davis JW, Lewis HD, et al. Response to influenza A vaccine among high-risk patients. South Med J 1979;72:29-32.
7 ASBMT GuidelinesExternal Web Site Icon
8 Danziger-Isakov LA, Husain S, Mooney ML, Hannan MM; for the ISHLT Infectious Diseases Council. The Novel 2009 H1N1 Influenza Virus Pandemic: Unique Considerations for Programs in Cardiothoracic Transplantation.
J Heart Lung Transplant. 2009 Oct 21. [Epub ahead of print]
9 Kumar D, Morris MI, Kotton CN et al. Guidance on Novel Influenza A/H1N1 in Solid Organ Transplant Recipients. American Journal of Transplantation 2009; 9: 1–8.
10 Lee N, Cockram CS, Chan PK, Hui DS, Choi KW, Sung JJ. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis 2008;46:1323-1324.
11 Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 2009;4(6):e6051.
12 Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-1944.
13 Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009;302:1880-1887.
14 Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med. 2009 Oct 2;361(17):1713-4.
15 Kidd IM, Down J, Nastouli E, Shulman R, Grant PR, Howell DC, Singer M. H1N1 pneumonitis treated with intravenous zanamivir. Lancet. 2009 Sep 19;374(9694):1036.
16Birnkrant D, Cox E. The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza. N Engl J Med. 2009 Nov 3. [Epub ahead of print]

Comments

H1N1 attacks the lungs- from CNN

H1N1 virus attacks deep into the lungs

By Stephanie Smith, CNN Medical Producer

December 8, 2009 4:18 p.m. EST

Damaged lung tissue is seen as light gray and healthy lung tissue is seen as dark gray in this cross-sectional CT scan of a deceased patient with pulmonary bacterial infection caused by the H1N1 virus. The other organs are white.

Damaged lung tissue is seen as light gray and healthy lung tissue is seen as dark gray in this cross-sectional CT scan of a deceased patient with pulmonary bacterial infection caused by the H1N1 virus. The other organs are white.

STORY HIGHLIGHTS

  • Doctors examined records, autopsy reports, and slides of 34 people who died due to H1N1
  • Inflammation and damage in the lungs extended all the way to the farthest end of airways
  • More than half of the deaths were caused by bacterial pneumonia.
  • 91 percent had underlying health condition; obesity was a factor in 72 percent of deaths

New York (CNN) — In the rare cases when the H1N1 virus kills, scientists have found, it penetrates deep into the lungs, creating widespread damage — a pattern similar to what killed millions during previous flu pandemics in 1918 and 1957.

The New York Office of Chief Medical Examiner examined medical records, autopsy reports and microscopic slides of 34 people with H1N1 who died between May 15 and July 9, 2009, during the early days of the pandemic.

The report found that among those deaths, inflammation and damage in the lungs extended all the way to the alveoli, tiny sacs at the farthest end of the lungs’ airways.

“Generally, flu stays in the upper airways,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. “What this shows is clearly this virus has capability of infecting and causing inflammation and destruction of cells from the trachea, all the way down into smaller cells of the lungs.

“The cells of the lung get directly attacked by the virus,” said Fauci.

CDC : Fewer states are reporting widespread flu activity

RELATED TOPICS

The damage appears in computerized scans as opaque patches that normally would not appear in the lungs, and which obstruct lung function.

Get complete coverage of H1N1 — Fighting the flu

Echoing previous reports, the study, published online in the Archives of Pathology and Laboratory Medicine, also revealed that 91 percent of those who died were people with underlying health problems, and most occurred in people between 25 and 49 years old.

More than half of the deaths were caused by bacterial pneumonia.

“The secondary bacterial infection evokes inflammation,” said Dr. William Schaffner, professor in the Division of Infectious Diseases at Vanderbilt University School of Medicine. “It socks it in the lung and all of a sudden the lung as an organ can’t do its principal job.”

Obesity was a factor in 72 percent of H1N1 deaths, a finding that has caused concern among infectious disease experts.

“That was a striking finding,” said Schaffner. “It contributes in a very material way to what we know about risks for a severe outcome with H1N1 infection. We are keeping an eye on obesity as a risk factor for H1N1 death.”

Track the H1N1 virus in your state

The study gives interesting insight into the mechanism behind H1N1 deaths, but will not change the current response to the virus, said Fauci.

Comments

Latest update on H1N1 from the CDC

Key Flu Indicators

Each week CDC analyzes information about influenza disease activity in the United States and publishes findings of key flu indicators in a report called FluView. During the week of November 15-21, 2009, influenza activity decreased in some key indicators and increased in others. Overall influenza activity remains high for this time of year. Below is a summary of the most recent key indicators:

  • Visits to doctors for influenza-like illness (ILI) nationally decreased sharply this week over last week with all regions showing declines in ILI. This is the fourth consecutive week of national decreases in ILI after four consecutive weeks of sharp increases While ILI has declined, visits to doctors for influenza-like illness remain high.
  • Influenza hospitalization rates remain higher than expected for this time of year. Hospitalization rates continue to be highest in younger populations with the highest hospitalization rate reported in children 0-4 years old.
  • The proportion of deaths attributed to pneumonia and influenza (P&I) based on the 122 Cities Report continues to be higher than expected for this time of year. This proportion has remained elevated for eight weeks now. In addition, 35 flu-related pediatric deaths were reported this week: 27 of these deaths were associated with laboratory confirmed 2009 H1N1; 7 were influenza A viruses, but were not subtyped and one death was associated with a seasonal influenza A (H1) virus. The one death associated with seasonal influenza A (H1) virus infection reported this week actually occurred in March, during the 2008-09 season. Since April 2009, CDC has received reports of 234 laboratory-confirmed pediatric deaths:  198 due to 2009 H1N1, 35 pediatric deaths that were laboratory confirmed as influenza, but the flu virus subtype was not determined, and one pediatric death associated with a seasonal influenza virus. (Laboratory-confirmed deaths are thought to represent an undercount of the actual number. CDC has provided estimates about the number of 2009 H1N1 cases and related hospitalizations and deaths.)
  • Thirty-two states are reporting widespread influenza activity at this time; a decline of 11 states from last week. They are: Alabama, Alaska, Arizona, California, Connecticut, Delaware, Florida, Idaho, Illinois, Indiana, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Utah, Vermont, Virginia, and West Virginia).
  • Almost all of the influenza viruses identified so far continue to be 2009 H1N1 influenza A viruses. These viruses remain similar to the virus chosen for the 2009 H1N1 vaccine, and remain susceptible to the antiviral drugs oseltamivir and zanamivir with rare exception.

*All data are preliminary and may change as more reports are received.

Learn more >>

U.S. Situation Update

Weekly Flu Activity Estimates

U.S. Patient Visits Reported for Influenza-like Illness (ILI)

U.S. Influenza-like Illness (ILI) Reported by Regions

U.S. Laboratory Confirmed Influenza-Associated Hospitalizations
and Deaths from August 30 to November 21, 2009

Posted November 30, 2009, 11:00 AM ET
Data reported to CDC by November 24, 2009, 12:00 AM ET

Cases Defined by

Hospitalizations

Deaths

Influenza Laboratory-Tests**
29,348
1,224

*Reports can be based on syndromic, admission or discharge data, or a combination of data elements that could include laboratory-confirmed and influenza-like illness hospitalizations.

*Laboratory confirmation includes any positive influenza test (rapid influenza tests, RT-PCR, DFA, IFA, or culture), whether or not typing was done.

The table shows aggregate reports of all laboratory confirmed influenza hospitalizations and deaths (including 2009 H1N1 and seasonal flu) since August 30, 2009 received by CDC from U.S. states and territories**. This table will be updated weekly each Friday at 11 a.m. For the 2009-2010 influenza season, states are reporting based on new case definitions for hospitalizations and deaths effective August 30, 2009.

CDC will continue to use its traditional surveillance systems to track the progress of the 2009-2010 influenza season. For more information about influenza surveillance, including reporting of influenza-associated hospitalizations and deaths, see Questions and Answers: Monitoring Influenza Activity, Including 2009 H1N1.

The number of 2009 H1N1 hospitalizations and deaths reported to CDC from April - August 2009 is available on the Past Situation Updates page.

For state level information, refer to state health departments.

International Human Cases of 2009 H1N1 Flu Infection
See: World Health Organization.

**States report weekly to CDC either 1) laboratory-confirmed influenza hospitalizations and deaths or 2) pneumonia and influenza syndrome-based cases of hospitalization and death resulting from all types or subtypes of influenza. Although only the laboratory confirmed cases are included in this report, CDC continues to analyze data both from laboratory confirmed and syndromic hospitalizations and deaths.

Comments

This week from the CDC – status of H1N1

CDC H1N1 Flu Website Situation Update, November 13, 2009?

Key Flu Indicators

Each week CDC analyzes information about influenza disease activity in the United States and publishes findings of key flu indicators in a report called FluView.* During the week of November 1-7, 2009, a review of key indicators found that certain indicators declined, while others continued to rise. Overall, flu activity in the United Sates remained very high. Below is a summary of the most recent key indicators:

  • Visits to doctors for influenza-like illness (ILI) nationally decreased this week over last week. This is the second week of national decreases in ILI after four consecutive weeks of sharp increases. (All regions but one showed declines in ILI. Region I (CT, ME, MA, NH, RI and VT) continues to show sharp increases in ILI activity. While ILI declined overall nationally, visits to doctors for influenza-like illness remain higher than what is seen during the peak of many regular flu seasons.
  • Total influenza hospitalization rates for laboratory-confirmed flu continue to climb and remain higher than expected for this time of year. Hospitalization rates continue to be highest in younger populations with the highest hospitalization rate reported in children 0-4 years old.
  • The proportion of deaths attributed to pneumonia and influenza (P&I) based on the 122 Cities Report continues to increase and has been higher than what is expected for six weeks now. In addition, 35 flu-related pediatric deaths were reported this week: 26 of these deaths were associated with laboratory confirmed 2009 H1N1; eight were influenza A viruses, but were not subtyped; and one was an influenza B virus. Since April 2009, CDC has received reports of 156 laboratory-confirmed pediatric 2009 H1N1 deaths, one influenza B death, and another 23 pediatric deaths that were laboratory confirmed as influenza, but the flu virus subtype was not determined.
  • Forty-six states are reporting widespread influenza activity at this time; a decline of two states over last week. They are: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. This many reports of widespread activity at this time of year are unprecedented during seasonal flu.
  • Almost all of the influenza viruses identified so far continue to be 2009 H1N1 influenza A viruses. These viruses remain similar to the virus chosen for the 2009 H1N1 vaccine, and remain susceptible to the antiviral drugs oseltamivir and zanamivir with rare exception

*All data are preliminary and may change as more reports are received.

Learn more >>

U.S. Situation Update

Weekly Flu Activity Estimates

U.S. Patient Visits Reported for Influenza-like Illness (ILI)

U.S. Influenza-like Illness (ILI) Reported by Regions

U.S. Laboratory Confirmed Influenza-Associated Hospitalizations
and Deaths from August 30 to November 7, 2009

Posted November 13, 2009, 11:00 AM ET
Data reported to CDC by November 10, 2009, 12:00 AM ET

Cases Defined by

Hospitalizations

Deaths

Influenza Laboratory-Tests**
22,364
877

*Reports can be based on syndromic, admission or discharge data, or a combination of data elements that could include laboratory-confirmed and influenza-like illness hospitalizations.

*Laboratory confirmation includes any positive influenza test (rapid influenza tests, RT-PCR, DFA, IFA, or culture), whether or not typing was done.

The table shows aggregate reports of all laboratory confirmed influenza hospitalizations and deaths (including 2009 H1N1 and seasonal flu) since August 30, 2009 received by CDC from U.S. states and territories**. This table will be updated weekly each Friday at 11 a.m. For the 2009-2010 influenza season, states are reporting based on new case definitions for hospitalizations and deaths effective August 30, 2009.

CDC will continue to use its traditional surveillance systems to track the progress of the 2009-2010 influenza season. For more information about influenza surveillance, including reporting of influenza-associated hospitalizations and deaths, see Questions and Answers: Monitoring Influenza Activity, Including 2009 H1N1.

The number of 2009 H1N1 hospitalizations and deaths reported to CDC from April – August 2009 is available on the Past Situation Updates page.

For state level information, refer to state health departments.

International Human Cases of 2009 H1N1 Flu Infection
See: World Health Organization External Web Site Icon.

**States report weekly to CDC either 1) laboratory-confirmed influenza hospitalizations and deaths or 2) pneumonia and influenza syndrome-based cases of hospitalization and death resulting from all types or subtypes of influenza. Although only the laboratory confirmed cases are included in this report, CDC continues to analyze data both from laboratory confirmed and syndromic hospitalizations and deaths.

U.S. Influenza-associated Pediatric Mortality
Posted November 13, 2009 (Updated each Friday)
Data reported to CDC by November 7, 2009

Date Reported

Laboratory-Confirmed 2009 H1N1 Influenza Pediatric Deaths

Laboratory-Confirmed Influenza A Subtype Unknown Pediatric Deaths

Laboratory-Confirmed
Seasonal
Influenza

Total

This Week  (Week 44, November 1-7, 2009)
26
8
1
35

Since August 30, 2009
98
19
0
117

Cumulative since April 26, 2009
156
22
1
179

This table is based on data reported to CDC through the Influenza-Associated Pediatric Mortality Surveillance System. Influenza-associated deaths in children (persons less than 18 years) was added as nationally notifiable condition in 2004.

For more information about influenza-associated pediatric mortality, see FluView.

For more information about the U.S. situation, see the CDC H1N1 Flu U.S. Situation page.

International Situation Update

This report provides an update to the international situation as of November 13, 2009. The World Health Organization (WHO) continues to report laboratory-confirmed 2009 H1N1 flu cases and deaths on its Web page. These laboratory-confirmed cases represent a substantial underestimation of total cases in the world, as many countries focus surveillance and laboratory testing only on people with severe illness. The 2009 H1N1 influenza virus continues to be the dominant influenza virus in circulation in the world. Since April 19, 2009, more than 65% of all influenza positive specimens reported to WHO have been 2009 H1N1. In temperate regions of the Southern Hemisphere, little disease activity due to 2009 H1N1 has been reported. In tropical regions of the Americas and Asia, influenza activity due to 2009 H1N1 remains variable. In temperate regions of the Northern Hemisphere, influenza-like illness (ILI) activity due to 2009 H1N1 continues to increase across many countries in Europe and Asia, as well as many areas of the United States, Mexico and Canada.

For more information about the international situation, see the CDC H1N1 Flu International Situation page.

CDC Releases New Widget:  5 in 5: Clinician Quick Facts for 2009 H1N1

Screen shot of new 5 in 5 Clinician Quick Facts for 2009 H1N1 widgetCDC released a new widget this week for clinicians. The “5 in 5: Clinician Quick Facts for 2009 H1N1″ widget provides five quick facts for health care providers and clinicians to consider when evaluating a patient for antiviral treatment. This and other CDC widgets are available at http://www.cdc.gov/widgets.

CDC Releases New Video: H1N1 Flu Vaccine – Why the Delay?

Screen shot of Video: H1N1 Flu Vaccine -- Why the Delay?Flu vaccine is the single best way to protect against influenza illness. Watch a short video to understand how flu vaccines are made, why manufacturing and shipping vaccine take so long, and how you can find flu vaccines near you.

You can learn more about flu vaccines at www.cdc.gov/h1n1flu or www.cdc.gov/flu.

To view and download links for other CDC videos, visit CDC-TV www.cdc.gov/CDCTV or CDC’s YouTube channel www.youtube.com/cdcstreaminghealth.

Recent Updates of Interest

Additional Updates on the CDC H1N1 Flu Website

To learn about other recent updates made to the CDC H1N1 Flu Website, please check the “What’s New” page on the CDC H1N1 Flu website.


Modify/Update Subscriber Preferences  |  Unsubscribe  |  Send Feedback  |  Learn more about CDC Email Updates
To receive the latest news for your region, please update your profile with your country, state and zip code.
Questions or problems?  Please contact support@govdelivery.com.

Department of Health and Human Services

Fight Flu with Facts! • Visit Flu.gov
Call 800-232-4636 • Text UPDATES to 87000

Centers for Disease Control and Prevention

Centers for Disease Control and Prevention (CDC) · 1600 Clifton Rd · Atlanta GA 30333 · 800-CDC-INFO (800-232-4636)

Comments

Swine Flu becomes National Emergency


October 24, 2009

Obama Declares Swine Flu a National Emergency

By THE ASSOCIATED PRESS

Filed at 11:23 a.m. ET

WASHINGTON (AP) — President Barack Obama has declared the swine flu outbreak a national emergency.

The White House on Saturday said Obama signed a proclamation that would allow medical officials to bypass certain federal requirements. Officials described the move as similar to a declaration ahead of a hurricane making landfall.

               swineflu

Swine flu is more widespread now than it’s ever been and has resulted in more than 1,000 U.S. deaths so far.

Health authorities say almost 100 children have died from the flu, known as H1N1, and 46 states now have widespread flu activity.

The White House said Obama signed the declaration on Friday evening.

Comments

Center for Medicare and Medicaid Services info on H1N1

Medicaid and the Children’s Health Insurance Program (CHIP) Coverage of the 2009 H1N1Flu Vaccine and Treatment

The 2009 H1N1 flu (sometimes referred to as “swine flu”) is caused by a new strain of influenza virus. It is causing illness in people. The virus spreads from person-to-person, probably in much the same way that regular seasonal flu viruses spread.The symptoms of the 2009 H1N1 flu are similar to the symptoms of regular seasonal flu.These symptoms include fever, cough, sore throat, runny or stuffy nose, body aches,headache, chills, and fatigue. A significant number of people who have been infected with the 2009 H1N1 flu virus also have reported diarrhea and vomiting.

If you have flu-like symptoms, call your doctor’s office right away.

 Is there a vaccine for the 2009 H1N1 flu, like there is for the seasonal flu? Yes. The initial doses of the 2009 H1N1 flu vaccine are currently available for those at highest risk for infection. Additional doses are scheduled for shipment each week.Who should get the 2009 H1N1 flu vaccine?


There are some groups of people who have a higher risk of getting the 2009 H1N1 flu than others. Therefore, the Centers for Disease Control and Prevention (CDC) has recommended that the following groups get their vaccine as soon as it becomes available in their area:

•Pregnant women •People who live with or care for children younger than 6 months of age•Healthcare and emergency medical services personnel•Persons between the ages of 6 months through 24 years•People ages 25 through 64 years who are at higher risk because of chronic health disorders or weakened immune systems

If you aren’t in one of the groups listed above, talk with your doctor about when to get the vaccine.

Note: If you are sick and need to be in close contact with someone who has a higher risk of getting the 2009 H1N1 flu, consider wearing a surgical mask or cover your nose and mouth with a tissue. Remember to wash your hands frequently.

Will Medicaid and the Children’s Health Insurance Program (CHIP) cover the 2009 H1N1 flu vaccine?

Yes. Medicaid and CHIP cover the 2009 HIN1 flu vaccine.Medicaid and CHIP will cover both a single dose of the seasonal flu vaccine and one or more doses of the 2009 H1N1 flu vaccine, if more than one dose is needed.

Talk to your doctor to find out how many doses you will need. Children and pregnant women will get the vaccine free of charge. Adults are covered if they get the vaccine at a public health department, physician office, Federally-qualified health center, or rural health clinic, but they may have to pay a small copayment.

You may get the vaccine at a hospital, but it’s only recommended if you can’t get to another site.

Your state is working with your local public health department to make it easy for you to get a vaccine. To find the most convenient site for you, call or visit your state’s public health department Web site. A listing of state public health departments can be found by visiting www.cdc.gov/h1n1flu/states.htm.

What if I get the 2009 H1N1 flu? Contact your doctor for advice on how to treat the 2009 H1N1 flu.
Medicaid and CHIP will cover your care, including an evaluation, any required tests, and your treatment. Children under 18 and pregnant women will get care free-of-charge while other adults may have to pay a small copayment.
There are drugs your doctor may prescribe for treating both seasonal and H1N1 flu called “antiviral drugs.” These drugs can make you better faster and may also prevent serious complications. This flu season, antiviral drugs are being used mainly to treat people who are very sick, such as people who need to be hospitalized, and to treat sick people who are more likely to get serious flu complications. Remember, most people with the 2009 H1N1 flu have had mild illness and haven’t needed medical care or antiviral drugs, and the same is true of seasonal flu.

Some states have preauthorization requirements for antiviral medications, such as Tamiflu or Relenza. This means that the prescription must be approved by the State where you live. This approval process can take 24 hours. If you are prescribed an antiviral medication, you are entitled to get at least 3 days worth of the prescription right away. The CDC recommends a full 5-day course of antiviral medication, so if you are unable to get 5 days worth of the prescription right away, make sure to go back to the pharmacy after 24 hours to pick up the rest.

Where can I find more information about the 2009 H1N1flu, including how the virus is spread and how to prevent it?

For more information about the 2009 H1N1 flu, visit www.flu.gov or the Centers for Disease Control Web site at www.cdc.gov/h1n1flu/general_info.htm. You can also call 1-800-CDC-INFO (1-800-232-4636) for more information.Where can I find out more about Medicaid or CHIP?


Call your State Medical Assistance (Medicaid) office for more information. Call 1-800-MEDICARE (1-800-633-4227) and say “Medicaid” to get the telephone number for your State Medical Assistance office. TTY users should call 1-877-486-2048. You can also visit www.medicare.gov.

Will Medicare cover the 2009 H1N1 flu vaccine? Yes. Medicare will cover administration of the 2009 H1N1 flu. Your doctor or healthcare provider can’t charge you for the 2009 H1N1 vaccine because they received thevaccine for free.You pay nothing for the 2009 H1N1 vaccine’s administration if your doctor or health careprovider accepts assignment. Assignment means that your doctor, provider, or supplier hassigned an agreement with Medicare to accept the Medicare-approved amount as full payment for covered services. The Part B deductible and coinsurance don’t apply to the2009 H1N1 vaccine or its administration.

Where can I find out more about Medicare?

For more information about Medicare, visit www.medicare.gov. You can also call 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048.

Comments

Where are the flu shots right now?

This is the best site for all you ever wanted to know about the Swine flu.  www.Flu.gov

There is a map with a drop down menu by state so that you can find out IF the vaccine is available, where it is, and if not, when it will be.

If you THINK you have the flu, it lists all of the symptoms.

If you want to avoid the flu, it gives handy tips.

If you have kids who want to know more- then Elmo can help explain.

10_07_elmo_rosita_thumbnail_spanish

It debunks false claims and fears.  See the section called Myths and Facts.

It warns of internet shopping for the vaccine.

ANYTHING you ever wanted to know about the H1N1 is located here.  Can your pet get it from you?   Find out.

Ask the expert? 

askexpert

Find out what illnesses or disease groups should and should not get this vaccine.

Again,

Go to www.Flu.gov for all of this valuable info

Comments

PIDD Patients and Swine Flu Shots

Swine Flu Shots Safe for People With Weak Immune Systems: Experts

Another study outlines risks of catching H1N1 from various routes

HealthDay
Friday, September 18, 2009

HealthDay news imageFRIDAY, Sept. 18 (HealthDay News) — The H1N1 swine flu vaccines approved this week by the U.S. Food and Drug Administration can be safely used by people with compromised immune systems, according to new recommendations from the American Academy of Allergy, Asthma & Immunology.

These would include people whose immune responses are weakened by medical treatments (such as for cancer or organ transplant) and those infected with HIV, the experts said.

Influenza vaccines can be made from live — but modified and weakened — virus, or they can be made from the harmless byproducts of the virus (so-called “killed” virus vaccines). According to the experts at the American Academy of Allergy, Asthma & Immunology (AAAAI), all of the injected H1N1 vaccines so far approved by the FDA are of the “killed” variety.

“There’s never any harm with giving killed influenza vaccine” to immuno-compromised individuals, said Dr. Kenneth Bromberg, director of the Vaccine Research Center at The Brooklyn Hospital Center in New York City.

There is one vaccine out there that those with weakened immune systems should avoid: the nasal spray form of the flu vaccine, FluMist. FluMist is already available as a seasonal flu vaccine, and 3.4 million doses of an H1N1 version of FluMist are expected to be distributed nationally the first week of October, CDC officials announced Friday.

FluMist is derived from live (but very weakened) virus, so it could pose a problem for people with poor immune systems. The recommendation to avoid FluMist extends to people living in close proximity to an immune-compromised person, such as family members, because they could pass on the live virus to that individual, the AAAAI said.

No such threat exists for average Americans with robust immune responses, the experts said.

One question for some people with compromised immune systems is whether the flu shot will actually help them, given their poor immune defenses.

People with so-called “primary” immune deficiency — rare immune deficiencies inherited at birth — can take the H1N1 vaccine, the academy said. “Although the antibody response may be poor or low [in these individuals], the cell-mediated response may be a helpful immune response to [fight] the virus,” AAAAI President-elect Dr. Mark Ballow said in a news release issued Thursday.

But, depending on their level of immune cell function, certain HIV-infected individuals may not be able to mount enough of an immune response to make flu vaccination worthwhile, the experts said.

“The issue is whether the compromised immune response might result in insufficient protection, not whether the inactivated H1N1 or seasonal influenza vaccine is excessively harmful,” said Dr. Paul Greenberger, president of AAAAI.

“The CDC (U.S. Centers for Disease Control and Prevention) notes that most HIV patients can receive the immunization, and from earlier studies with seasonal flu shots, [it appears] there may be a reduced response if the number of CD4+ lymphocytes is less than 100/mm3,” Greenberger said. “Better responses occurred if patients had CD4+ lymphocyte counts of at least 400.”

He added that “studies haven’t been published yet of H1N1 vaccination in HIV patients.”

In other swine flu news, a study published in the September issue of the journal Risk Analysis seeks to quantify the risk from various routes of transmission of the swine flu virus. Researchers from the University of California, Berkeley, and the University of Illinois used sophisticated modeling and pored over the available data on four key means of person-to-person H1N1 transmission.

They speculate that hand contact with a contaminated surface brings a 31 percent risk of actual infection; inhaling tiny particles laden with virus in a room brings a 17 percent likelihood of infection; close contact where coughs spray viral-laden droplets onto the eyes, nostrils or lips brings a 52 percent chance of infection. Inhaling relatively large particles carrying virus when three feet or nearer to an infected person carries only a 0.52 percent risk for infection, the research team said.

According to the researchers, the study strengthens current recommendations to cover the mouth when coughing and to disinfect commonly touched surfaces.

SOURCE: Paul Greenberger, M.D., president, American Academy of Allergy, Asthma & Immunology; Kenneth Bromberg, M.D., director, Vaccine Research Center, The Brooklyn Hospital Center, New York City; Sept. 17, 2009, news release, American Academy of Allergy, Asthma & Immunology; Sept. 16, 2009, news release, Society for Risk Analysis

Comments

Characteristics of Swine Flu from the Washington Post

Swine Flu Characteristics Becoming More Evident
Links to Pneumonia, Rapid Effects on Young Noted

By Rob Stein
Washington Post Staff Writer
Saturday, October 17, 2009

As swine flu continues to spread around the globe, a clearer and in some ways more unnerving picture of the most serious cases has started to emerge, indicating that the virus could pose a greater threat to some young, otherwise vibrant people.

The virus can cause life-threatening viral pneumonia much more commonly than the typical flu, prompting the World Health Organization on Friday to warn hospitals to prepare for a possible wave of very sick patients and to urge doctors to treat suspected cases quickly with antiviral drugs.

Experts stress that most people who get the H1N1 virus either never get sick or recover easily. But some young adults, possibly especially women, are falling seriously ill at an unexpectedly rapid pace and are showing up in intensive care units and dying in unusually high numbers, they say.

Although why a minority of patients become so sick remains a mystery, new research indicates that H1N1 is different from typical seasonal flu viruses in crucial ways — most notably in its ability to penetrate deep into the lungs and cause viral pneumonia.

“It’s not like seasonal influenza,” Nikki Shindo of the World Health Organization said at the conclusion of a three-day meeting of more than 100 experts the WHO convened in Washington to review swine flu. “It can cause very severe disease in previously healthy young adults.”

Meanwhile, the Centers for Disease Control and Prevention reported Friday that vaccine production was proceeding more slowly than hoped. Officials had predicted that about 40 million doses would be available by the end of October, but that projection will probably fall short by about 10 million to 12 million doses, said Anne Schuchat, director of the CDC’s National Center for Immunization and Respiratory Diseases.

“Eventually, anyone who wants to be vaccinated will be able to be, but the next couple of weeks will continue to be a slow start,” she said. So far, 11.4 million doses have become available and states have ordered about 8 million doses, but the vaccine will not become available in large amounts until November, she said.

The WHO’s warning came as U.S. health officials reported that the number of states reporting widespread flu activity was up to 41, including Maryland and Virginia, and that the death toll among children had climbed to 86. Maryland has reported 10 deaths and Virginia health officials say eight people, including one child, have died. There have been no reports of deaths among District residents.

Swineflukids

So far, the virus does not seem to sicken or kill people more often than the typical flu. But the pattern of people getting seriously ill is far different than in typical flu seasons. The elderly, who are usually most vulnerable, are generally spared; children, teenagers, pregnant women and young adults are the most common victims.

Officials have been closely monitoring the virus for signs it has mutated into a more dangerous form, and they have also been testing animals for the virus because of fears that infected livestock could cause more-lethal mutations.

Federal agriculture officials said Friday that pigs from the Minnesota State Fair had tested positive for H1N1, which would make them the first documented pig infections in the United States, if follow-up tests confirm the results. But there are no signs that the pigs were sick or that the animals had infected any humans. Children staying near the fair had gotten the virus, but there was no sign they were infected by the pigs.

Seasonal flu viruses tend to infect primarily the upper respiratory system. But recent animal studies and autopsies on about 100 swine flu victims show that H1N1 infects both the upper respiratory tract, which makes it relatively easy to transmit, and also the lungs, which is more similar to the avian flu virus that has been circulating in Asia.

“It’s like the avian flu on steroids,” said Sherif Zaki, chief of Infectious Disease Pathology at the CDC. He noted that unusually large concentrations of the swine flu virus have been found in the lungs of victims: “It really is a new beast, so to speak.”

About a third of patients who required intensive care had bacterial pneumonia, but H1N1’s proclivity to infect lung cells makes it more likely than seasonal flu to cause viral pneumonia, which can lead to life-threatening lung damage.

“Remarkably different is this small subset of patients that presents very severe viral pneumonia,” Shindo said.

One of those patients was Karen Ann Hays of Sacramento, Calif., an otherwise healthy nurse whose hobby was tackling grueling triathlons. Despite desperate measures to keep her alive, Hays, 51, died in July within days of coming down with swine flu.

“I have seen more cases like this in the last three months than I have in the last 30 years,” said Peter Murphy, director of intensive care at the Mercy San Juan Medical Center in Carmichael, Calif., who tried to save Hays.

Although it remains unclear how frequently the virus makes people seriously ill, recent reports from Mexico, Canada, the United States, Australia and New Zealand indicate that perhaps 1 percent of patients who get infected require hospitalization. Between 12 to 30 percent of those hospitalized need intensive care, and 15 to 40 percent of those in intensive care die.

While about two-thirds of U.S. patients who were hospitalized in the spring had other medical conditions, the CDC reported this week that an analysis of more than 1,400 hospitalized victims found perhaps half had no serious health problems.

About one-third of those around the world who have died or became seriously ill from swine flu appear to have been vulnerable because they had heart or lung disease, chronic kidney problems, or other ailments that usually put people at risk. But others had conditions that many may not immediately associate with frailness, such as mild asthma, high blood pressure, high cholesterol and obesity.

“Many of these people look just like you or me,” said Anand Kumar, an associate professor of critical care and infectious disease at the University of Manitoba in Winnipeg, Canada, which was hit hard by the pandemic’s first wave last spring.

There appears to be no way to predict with certainty who may suffer serious, life-threatening complications, since some victims have had no other health problems.

For instance, Stacey Hernandez Speegle, 30, of Madison, Calif., who died in July, “was in great shape. She was on the softball team. She had two young children. She was renovating her house,” said her mother, Tamara Brooks. “It’s just so hard to believe.”

Although it has been well publicized that pregnant women appear to be at increased risk, some evidence has started to suggest that being female may itself be a risk factor, for reasons that remain unclear.

“There’s no question that women, and particularly young women, are getting hit disproportionately,” said Kumar. He noted that women tend to have more fat tissue, which can help stimulate a dangerous inflammatory response to infections.

And some of those who develop serious illness deteriorate soon after starting to feel ill. They require oxygen masks, ventilator machines to pump oxygen into their lungs to keep them alive, and drastic, often rarely used measures to try to save them within days of the first fever, ache or cough.

“The rapidity of it is striking,” said Andrew R. Davies, deputy director of intensive care at Alfred Hospital in Melbourne, Australia.

Some of the cases in Australia and New Zealand were so severe that doctors resorted to a much more aggressive, less commonly used treatment known as extracorporeal membrane oxygenation (ECMO). It involves siphoning patients’ blood into a machine to remove carbon dioxide and then infuse it with oxygen before returning it to their bodies.

“It’s quite an extreme form of treatment,” said Steve Webb, a clinical associate professor at the Royal Perth Hospital in Australia.

Other doctors have tried administering nitric oxide and putting patients in a bed that turns them upside down to help their lungs work better. “Our back was against the wall,” Murphy said, adding that after the deaths of patients such as Hays his hospital is working to make ECMO available.

“It’s very difficult to get this double-barreled message out that: ‘Yes, most cases are mild, but in a small percentage of cases these cases are disastrous,’ ” Vanderbilt University’s William Schaffner said. “But the message is: Don’t underestimate H1N1.”

Of the at least 86 Americans younger than 18 who have died from H1N1, 11 deaths were reported in the past week. About half of the deaths in the past month were among teenagers, Schuchat said. Since Aug. 30, 43 pediatric deaths have been reported, including three in those younger than age 2, five among those ages 2 to 4, 16 in those ages 5 to 11, and 19 among those ages 12 to 17, she said.

“These are very sobering statistics,” Schuchat said, noting that only about 40 or 50 children usually die during an entire flu season.

Virginia Health Commissioner Karen Remley said Friday that although the majority of H1N1 cases in the state are “mild and moderate,” significant numbers have become seriously ill.

In Maryland, at least 257 people have been hospitalized with confirmed cases of H1N1 since June, health officials said.

At least 2,914 Americans have died from flu-related illnesses since the H1N1 began, the CDC said.

Staff researcher Madonna Lebling and staff writer Michael Laris contributed to this report.

Comments

« Previous entries